---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-038211"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2025-12-18T23:59:59+00:00"
generated_at: "2026-05-16T12:43:15.497844+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# DiaMedica provides DM199 preeclampsia update after FDA pre-IND meeting; additional rabbit study required

## Summary
- FDA requested one non-clinical 10-day rabbit EFD/PPND study; results expected by Q2 2026.
- Phase 2 investigator-sponsored trial in South Africa has dosed over 30 women with late-stage PE.
- Interim data: statistically significant blood pressure reductions, uterine artery dilation, no placental transfer.
- Regulatory clarity obtained for IND submission to study DM199 in early-onset preeclampsia.

## SEC filing metadata
- accession: 0001437749-25-038211
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2025-12-18T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774925038211/0001437749-25-038211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774925038211/dmtp20251217_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-038211
- JSON: https://secwatch.observer/filing/0001437749-25-038211.json
- Plain text: https://secwatch.observer/filing/0001437749-25-038211.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.